Tarsus Pharmaceuticals (TARS) Competitors $55.37 -0.26 (-0.47%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, and CRSPShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Grifols Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics Tarsus Pharmaceuticals (NASDAQ:TARS) and Grifols (NASDAQ:GRFS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Which has better valuation & earnings, TARS or GRFS? Grifols has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M12.77-$115.55M-$2.33-23.76Grifols$7.81B0.86$169.80M$1.178.39 Is TARS or GRFS more profitable? Grifols has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Grifols' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Grifols N/A N/A N/A Does the media refer more to TARS or GRFS? In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 2 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.78 beat Grifols' score of 1.13 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TARS or GRFS? Tarsus Pharmaceuticals currently has a consensus target price of $66.67, suggesting a potential upside of 20.40%. Grifols has a consensus target price of $10.30, suggesting a potential upside of 4.94%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility and risk, TARS or GRFS? Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Do insiders & institutionals hold more shares of TARS or GRFS? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryTarsus Pharmaceuticals and Grifols tied by winning 8 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.34B$3.12B$5.71B$10.36BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-23.7620.9076.4126.50Price / Sales12.77255.07469.6091.99Price / CashN/A46.3537.4661.85Price / Book9.439.7713.136.40Net Income-$115.55M-$52.73M$3.29B$271.39M7 Day Performance7.12%4.37%2.40%2.73%1 Month Performance-3.29%5.89%4.42%7.23%1 Year Performance67.63%18.56%73.40%29.46% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.2291 of 5 stars$55.37-0.5%$66.67+20.4%+67.7%$2.34B$182.95M-23.7650GRFSGrifols3.9318 of 5 stars$9.63-2.5%$10.30+7.0%+11.9%$6.79B$7.81B8.2323,822RYTMRhythm Pharmaceuticals3.2599 of 5 stars$96.03-0.2%$101.57+5.8%+93.3%$6.39B$156.29M-31.90140Positive NewsABVXAbivax2.4446 of 5 stars$85.87+2.2%$99.43+15.8%+655.2%$6.35BN/A0.0061Gap UpCYTKCytokinetics4.232 of 5 stars$49.44-3.3%$75.38+52.5%-6.8%$6.12B$18.47M-9.69250Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.1512 of 5 stars$33.88+2.3%$74.22+119.1%-28.3%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.85 of 5 stars$116.78-1.4%$177.86+52.3%+29.1%$5.91B$495.03M-23.03380Insider TradeNUVLNuvalent3.1209 of 5 stars$79.37-1.4%$120.91+52.3%-20.5%$5.80BN/A-16.2040RNAAvidity Biosciences2.0717 of 5 stars$40.22-10.1%$68.94+71.4%-2.8%$5.76B$10.90M-11.30190Analyst ForecastMRUSMerus3.1601 of 5 stars$68.09-2.1%$88.75+30.3%+42.8%$5.26B$36.13M-12.3837Positive NewsCRSPCRISPR Therapeutics3.237 of 5 stars$57.84+2.8%$71.60+23.8%+30.0%$5.12B$37.31M-10.65460Analyst Forecast Related Companies and Tools Related Companies Grifols Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives Cytokinetics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Nuvalent Alternatives Avidity Biosciences Alternatives Merus Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts